ziprasidone has been researched along with Body Weight in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (61.54) | 29.6817 |
| 2010's | 15 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crespo-Facorro, B; Díaz Martínez, Á; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suárez Pinilla, P; Vázquez-Bourgon, J | 1 |
| Hong, JP; Kim, MS; Park, S; Yi, KK | 1 |
| Bobes García, J; de la Gándara Martín, JJ; Gutiérrez Fraile, M | 1 |
| Blasey, C; Davis, JM; Kraemer, H; Lieberman, JA; Reaven, GM; Schatzberg, AF; Sethuraman, G; Tsuang, MT | 1 |
| Galluzzo, A; Gorini, B; Romeo, F; Sacchetti, E; Valsecchi, P; Warrington, L | 2 |
| Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Forstbauer, SI; Freudenreich, O; Goff, DC; Henderson, DC; Miley, K; Sharma, B | 1 |
| Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Thys, E; van Veelen, NM; Verkes, RJ | 1 |
| Baik, JH; Choi, SY; Noh, JS; Yoon, S | 1 |
| Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
| Celikyurt, IK; Erden, FB; Kayir, H; Ulak, G; Ulusoy, GK; Uzbay, TI | 1 |
| Bachinsky, M; Cavus, I; Chappell, P; Glue, P; Karayal, ON; Kolluri, S; Stewart, M | 1 |
| Calabrese, JR; Ice, KS; Karayal, ON; Kemp, DE; Pappadopulos, E; Sachs, GS; Siu, CO; Vieta, E | 1 |
| Cucchiaro, J; Loebel, A; Ogasa, M; Potkin, SG | 1 |
| Kaushik, S; Khan, A; Lindenmayer, JP; Parakadavil, M; Smith, RC; Tedeschi, F; Yusim, A | 1 |
| Hong, JP; Kim, MS; Namkoong, C; Park, MH; Park, S | 1 |
| Chung, YC; Huang, GB; Kim, MG; Lee, KH; Park, TW; Yang, JC; Zhao, T | 1 |
| Kolluri, S; Newcomer, JW; Pappadopulos, E | 1 |
| Chen, HH; Fan, X; Gao, K; Guo, XF; Ou, JJ; Wang, J; Wu, RR; Xu, Y; Zhao, JP | 1 |
| Cohen, S; Fitzgerald, B; Khan, A; Khan, S; Okos, A | 1 |
| Daniel, DG; Romano, SJ; Simpson, G; Weiden, PJ | 1 |
| Arnold, G; Meisel, A; Winter, C; Zschenderlein, R | 1 |
| Brown, RR; Estoup, MW | 1 |
| Allison, DB; Casey, DE; Cope, MB; Fernández, JR; Geary, N; Nagy, TR | 1 |
| Fell, MJ; Gibson, R; Marshall, KM; McDermott, E; Neill, JC; Sisodia, G | 1 |
| Kostulski, A; Rabe-Jabłońska, J; Wyszogrodzka-Kucharska, A | 1 |
| Jones, DN; Kalinichev, M; Rourke, C | 1 |
| Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS | 1 |
| de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D | 1 |
| Baumgartner, S; Ebenbichler, C; Edlinger, M; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Rettenbacher, MA | 1 |
| Balbo, E; Delgado, JF; Diez, T; Martin, E; Montes, JM; Rodriguez, JL; Sopelana, P; Soto, JA; Villardaga, I | 1 |
| Domin, S; Kasper, S; Kudla, D; Lambert, M; Naber, D | 1 |
| Colasanti, A; Dragogna, F; Fiorentini, A; Mauri, MC; Papa, P; Rossattini, M; Valli, A; Volonteri, LS | 1 |
| Anjum, N; Cheetham, S; Dickinson, K; Fell, MJ; Marshall, KM; Neill, JC; Peltola, LM; Vickers, S | 1 |
| Lebovitz, HE; Loebel, AD; Newcomer, JW; Weiden, PJ; Yang, R | 1 |
| Gibel, A; Ratner, Y; Ritsner, MS; Yorkov, V | 1 |
| Aleardi, M; Biederman, J; Dougherty, M; Mick, E; Spencer, T; Wozniak, J | 1 |
| Fayek, M; Kingsbury, SJ; Simpson, GM; Trufasiu, D; Zada, J | 1 |
| Caley, CF; Cooper, CK | 1 |
3 review(s) available for ziprasidone and Body Weight
| Article | Year |
|---|---|
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Body Mass Index; Body Weight; Clinical Trials as Topic; Drug Industry; Fasting; Humans; Lipids; Piperazines; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Time Factors | 2012 |
[Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
Topics: Antipsychotic Agents; Body Weight; Clozapine; Dibenzothiazepines; Humans; Hyperlipidemias; Leptin; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles; Weight Gain | 2005 |
Ziprasidone: the fifth atypical antipsychotic.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Headache; Humans; Injections, Intramuscular; Long QT Syndrome; Nausea; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain | 2002 |
22 trial(s) available for ziprasidone and Body Weight
| Article | Year |
|---|---|
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Triglycerides; Young Adult | 2018 |
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Appetite; Benzodiazepines; Body Composition; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Energy Metabolism; Female; Humans; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2013 |
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Hyperglycemia; Lipid Metabolism; Lipoproteins, HDL; Male; Middle Aged; Olanzapine; Piperazines; Prediabetic State; Predictive Value of Tests; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Body Weight; Clozapine; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Italy; Lipids; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Young Adult | 2009 |
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Clozapine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Male; Middle Aged; Morbidity; Olanzapine; Piperazines; Schizophrenia; Thiazoles; Time Factors | 2009 |
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Topics: Adult; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Basal Ganglia Diseases; Benzodiazepines; Biperiden; Blood Glucose; Body Weight; Cholesterol; Chronic Disease; Electrocardiography; Female; Humans; Male; Muscarinic Antagonists; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Triglycerides; Young Adult | 2011 |
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Body Weight; Clozapine; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Italy; Lipids; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Young Adult | 2009 |
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult | 2010 |
Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Cholesterol; Cognition; Dibenzothiazepines; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Treatment Outcome; Triglycerides; Young Adult | 2011 |
Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.
Topics: Adjuvants, Immunologic; Antipsychotic Agents; Bipolar Disorder; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lithium Chloride; Longitudinal Studies; Male; Metabolic Diseases; Metabolome; Piperazines; Psychiatric Status Rating Scales; Thiazoles; Valproic Acid | 2012 |
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Body Weight; Cholesterol; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2011 |
Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Patient Dropouts; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Thiazoles | 2012 |
Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Glucose; Humans; Insulin; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Schizophrenia; Thiazoles; Young Adult | 2013 |
Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation.
Topics: Antipsychotic Agents; Blood Glucose; Body Weight; Cholesterol; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intellectual Disability; Lipids; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Thiazoles; Treatment Outcome; Triglycerides | 2003 |
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Female; Health Status Indicators; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Withholding Treatment | 2003 |
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Cross-Over Studies; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Olanzapine; Patient Dropouts; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Thiazoles; Time Factors; Treatment Outcome | 2006 |
Early changes of plasma lipids during treatment with atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Clozapine; Humans; Lipids; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Triglycerides | 2006 |
Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Chromatography, High Pressure Liquid; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles | 2007 |
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
Topics: Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Lipids; Male; Mental Disorders; Olanzapine; Piperazines; Retrospective Studies; Single-Blind Method; Thiazoles; Time Factors | 2008 |
Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Topics: Adult; Antipsychotic Agents; Body Weight; Chronic Disease; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles | 2007 |
A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
Topics: Antipsychotic Agents; Bipolar Disorder; Body Weight; Evaluation Studies as Topic; Female; Humans; Male; Pediatrics; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Thiazoles | 2007 |
The apparent effects of ziprasidone on plasma lipids and glucose.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lipids; Male; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Triglycerides | 2001 |
14 other study(ies) available for ziprasidone and Body Weight
| Article | Year |
|---|---|
Switching to ziprasidone in the clinical practice setting: an open-label study.
Topics: Adult; Antipsychotic Agents; Body Weight; Brief Psychiatric Rating Scale; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychometrics; Psychotic Disorders; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2013 |
Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Eating; Male; Mice; Mice, Knockout; Motor Activity; Olanzapine; Piperazines; Receptors, Dopamine D2; Risperidone; Thiazoles; Weight Gain | 2010 |
Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Central Nervous System Depressants; Comorbidity; Dibenzothiazepines; Ethanol; Humans; Hyperkinesis; Male; Motor Activity; Piperazines; Psychomotor Agitation; Quetiapine Fumarate; Rats; Rats, Wistar; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Thiazoles; Time Factors | 2011 |
Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
Topics: Analysis of Variance; Antipsychotic Agents; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Insulin; Lipids; Male; Metabolic Syndrome; Middle Aged; Piperazines; Polypharmacy; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
The effect of ziprasidone on body weight and energy expenditure in female rats.
Topics: Abdominal Fat; Adiposity; Animals; Antipsychotic Agents; Body Temperature; Body Weight; Eating; Energy Metabolism; Female; Motor Activity; Piperazines; Rats; Rats, Sprague-Dawley; Thiazoles | 2012 |
Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride.
Topics: Adult; Antipsychotic Agents; Body Weight; Female; Humans; Obesity; Piperazines; Thiazoles; Tiapamil Hydrochloride; Tourette Syndrome; Weight Gain | 2004 |
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Electrocardiography; Female; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Olanzapine; Piperazines; Retrospective Studies; Schizophrenia; Thiazoles; Triglycerides | 2005 |
Antipsychotic drug-induced weight gain: development of an animal model.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Constitution; Body Weight; Dibenzothiazepines; Eating; Male; Mice; Mice, Inbred C57BL; Models, Animal; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Thiazoles | 2005 |
Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Drinking; Female; Piperazines; Rats; Thiazoles; Time Factors | 2005 |
Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Olanzapine; Piperazines; Prolactin; Rats; Rats, Sprague-Dawley; Thiazoles; Weight Gain | 2006 |
A model for antipsychotic-induced obesity in the male rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Haloperidol; Male; Obesity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors; Weight Gain | 2006 |
Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Cholesterol; Female; Humans; Male; Metabolic Diseases; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Severity of Illness Index; Statistics, Nonparametric; Thiazoles; Time Factors | 2007 |
Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Austria; Blood Glucose; Body Weight; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Lipids; Male; Middle Aged; Patient Dropouts; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychotic Disorders; Quality of Life; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.
Topics: Adiposity; Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Composition; Body Weight; Cholesterol; Drinking; Eating; Energy Metabolism; Fatty Acids, Nonesterified; Female; Food Preferences; Glycerol; Insulin; Leptin; Motor Activity; Olanzapine; Piperazines; Prolactin; Rats; Risperidone; Thiazoles; Triglycerides | 2007 |